Monday, April 27, 2015| Latest E-book
You are here:
Pharma
#

Pharma

Articles

View all

Daiichi Sankyo's misery ends, block deal to give company coup de grce

Apr 22, 2015

Daiichi Sankyo's misery ends, block deal to give company coup de grce

Even after allowing for control premium, the price that Daiichi Sankyo paid for Ranbaxy Laboratories was clearly excessive, and those in the know said sagely that winners curse would have its say sooner than later. #Ranbaxy Laboratories #Sun Pharma #CompanyWatch #Daiichi Sankyo #Diageo #USFDA #United Spirits #Dilip Sanghvi
Daiichi Sankyo to exit Sun Pharma, sell its 9% stake for up to Rs 22,000 cr

Apr 21, 2015

Daiichi Sankyo to exit Sun Pharma, sell its 9% stake for up to Rs 22,000 cr

The shares are being sold in the indicative price band of between 930 rupees and 1,043.80 rupees apiece #Sun Pharma #Ranbaxy #Daiichi Sankyo #Dilip Shanghvi
Exit strategy: Daiichi Sankyo to sell entire stake in Sun Pharma worth Rs 22,000 cr

Apr 21, 2015

Exit strategy: Daiichi Sankyo to sell entire stake in Sun Pharma worth Rs 22,000 cr

Daiichi is planning to sell the nearly 9% stake it currently holds in Indian pharma major Sun Pharmaceuticals, worth about Rs 22,300 crore at Monday's close of market, through block deals on Tuesday. #Sun Pharma #Ranbaxy #Daiichi Sankyo #Shasun Pharmaceuticals
Revelry in markets as healthy IIP pushes Sensex, Nifty over one-month high

Apr 13, 2015

Revelry in markets as healthy IIP pushes Sensex, Nifty over one-month high

The 50-share NSE Nifty ended above the 8,800-level by rising 53.65 points or 0.61 per cent to 8,834.00 after shuttling between 8,841.65 and 8,762.10 intra-day. #Business #Sensex #Hindalco #Bharti Airtel #nifty #Sun Pharma #IIP #BSE #NSE #BHEL #Areva #MarketClose

BLOG POSTS

View all

It's not just Ranbaxy, our health care regulators have failed us too

May 23, 2013

It's not just Ranbaxy, our health care regulators have failed us too

The Ranbaxy saga of fraud and greed goes beyond that. In India, it shows how our regulators too have failed us. #TheLongView #Health #Drugs #Ranbaxy #Healthcare #Pharma
Why a global fight against cancer is a good idea

Apr 10, 2013

Why a global fight against cancer is a good idea

In a substantive paper published today in the journal Nature Reviews, a group of authors from Singapore, the USA and Brazil evaluate the cost of cancer medication in low and middle income countries. #WhyNow #Cancer #Healthcare #Diabetes #Novartis #glivec #Merck #Dabur Pharma